Communication on risk of eye disorders with use of Lariam® (mefloquine)

Roche would like to inform healthcare professionals of an increased risk of eye disorders including cataract, retinal disorders and optic neuropathy which may occur with latency during or after treatment with Lariam®. These eye disorders can present with visual impairment and blurred vision. This increased risk of eye disorders was based on outcomes of review of available evidence from non-clinical studies, Roche global drug safety database and published literature. Patients on treatment with Lariam® who experiences visual disorders should be referred to his treating physician as certain conditions such as retinal disorders or optic neuropathy may require stopping treatment with the drug. Adverse events may occur or persist up to several weeks after discontinuation of Lariam® due to the long half-life of the drug. The package insert for Lariam® will be updated to reflect the new safety information.